Indirect airway challenges

European Respiratory Journal

Volumn 21, Issue 6, 2003, Pages 1050-1068

  Joos, Guy F ^a   O'Connor, B ^a   Anderson, S D ^a   Chung, F ^a   Cockcroft, D W ^a   Dahlen B ^a   DiMaria, G ^a   Foresi, A ^a   Hargreave, F E ^a   Holgate, S T ^a   Inman, M ^a   Lotvall J ^a   Magnussen, H ^a   Polosa, R ^a   Postma, D S ^a   Riedler, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adenosine; Asthma; Bronchoprovocation; Chronic obstructive pulmonary disease; Exercise; Methacholine

Indexed keywords

ACETYLCHOLINE; ADENOSINE; ANTIINFLAMMATORY AGENT; AUTACOID; BACTERIUM LIPOPOLYSACCHARIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ; CARBACHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; ENDOTOXIN; FUROSEMIDE; HEPARIN; HISTAMINE; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; MANNITOL; METHACHOLINE; NEDOCROMIL; OZONE; PROPRANOLOL; PROSTAGLANDIN D2; SODIUM CHLORIDE; STEROID; SULFUR OXIDE; TACHYKININ; THROMBOCYTE ACTIVATING FACTOR; UNINDEXED DRUG;

AEROSOL; AIRWAY; AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; BRONCHOSPASM; BRONCHUS; BRONCHUS HYPERREACTIVITY; DISEASE COURSE; DISEASE MARKER; DIVING; DOSE RESPONSE; DRUG EFFECT; EXERCISE; EXERCISE INDUCED ASTHMA; HUMAN; HYPERVENTILATION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATORY CELL; INTERMETHOD COMPARISON; MEDIATOR RELEASE; PREVALENCE; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SENSITIVITY AND SPECIFICITY; SMOOTH MUSCLE CONTRACTION; SPUTUM ANALYSIS; STANDARDIZATION; TACHYPHYLAXIS;

EID: 0038652066     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00008403     Document Type: Review

References (237)

1. Sterk PJ, Fabbri LM, Quanjer PhH, el al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests. European Community for Steel and Coal. Official position of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 53-83.
2. Lötvall J, Inman M, O'Byrne P. Measurement of airway hyperresponsiveness: new considerations. Thorax 2000; 53: 419-424.
3. Tashkin DP, Altose MD, Bleecker ER, et al. The lung health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis 1992; 145: 301-310.
4. Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine - relationship to minimum treatment to control symptoms of asthma. Thorax 1981; 36: 575-579.
5. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996; 153: 1802-1811.
6. Pauwels R, Joos G, Van der Straeten M. Bronchial hyperresponsiveness is not bronchial hyperresponsiveness is not bronchial asthma. Clin Allergy, 1988; 18: 317-321.
7. Van Schoor J, Joos GF, Pauwels RA. Indirect bronchial hyperresponsiveness in asthma: mechanisms, pharmacology and implications for clinical research. Eur Respir J 2000; 16: 514-533.
8. Manning PJ, Watson RM, O'Byrne PM. Exercise-induced refractoriness in asthmatic subjects involves leukotriene and prostaglandin interdependent mechanisms. Am Rev Respir Dis 1993; 148: 950-954.
9. Laprise C, Boulet LP. Magnitude and determinants of short-term tachyphylaxis to methacholine in subjects with symptomatic or asymptomatic airway hyperresponsiveness and in normal controls. Respiration 1996; 63: 304-308.
10. Strban M, Manning PJ, Watson RM, O'Byrne PM. Effect of magnitude of airway responsiveness and therapy with inhaled corticosteroid on histamine tachyphylaxis in asthma. Chest 1994; 105: 1434-1438.
11. Van Den Berg G, Meijer RJ, Kerstjens HA, et al. Pc(20) adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than pc(20) methacholine. Am J Respir Crit Care Med 2001; 163: 1546-1550.
12. van Velzen E, van den Bos JW, Benckhuijsen JA, van Essel T, de Bruijn R, Aalbers R. Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma. Thorax 1996; 51: 582-584.
13. Hofstra WB, Neijens HJ, Duiverman EJ, et al. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol 2000; 29: 415-423.
14. Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237-243.
15. McFadden ER, Jr., Gilbert IA. Exercise-induced asthma. N Engl J Med 1994; 330: 1362-1367.
16. Anderson SD, Daviskas E. The mechanism of exercise-induced asthma is ... J Allergy Clin Immunol 2000; 106: 453-459.
17. Eggleston PA, Kagey-Sobotka A, Lichtenstein LM. A comparison of the osmotic activation of basophils and human lung mast cells. Am Rev Respir Dis 1987; 135: 1043-1048.
18. Patel KR. Terfenadine in exercise induced asthma. Br Med J (Clin Res Ed ) 1984; 288: 1496-1497.
19. Finnerty JP, Holgate ST. Evidence for the roles of histamine and prostaglandins as mediators in exercise-induced asthma: the inhibitory effect of terfenadine and flurbiprofen alone and in combination. Eur Respir J 1990; 3: 540-547.
20. Magnussen H, Reuss G, Jorres R, Aurich R. The effect of azelastine on exercise-induced asthma. Chest 1988; 93: 937-940.
21. O'Sullivan S, Roquet A, Dahlen B, et al. Evidence for mast cell activation during exercise-induced bronchoconstriction. Eur Respir J 1998; 12: 345-350.
22. Nagakura T, Obata T, Shichijo K, et al. GC/MS analysis of urinary excretion of 9alpha, 11beta-PGF2 in acute and exercise-induced asthma in children. Clin Exp Allergy 1998; 28: 181-186.
23. Kikawa Y, Miyanomae T, Inoue Y, Salto M, Makai A, Sudo M. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol 1992; 89: 1111-1119.
24. Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52: 1030-1035.
25. Pliss LB, Ingenito EP, Ingram RHJ, Pichurko B. Assessment of bronchoalveolar cell and mediator response to isocapnic hyperpnea in asthma. Am Rev Respir Dis 1990; 142: 73-78.
26. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1740-1744.
27. Van Schoor J, Joos GF, Kips JC, Drajesk JF, Carpentier PJ, Pauwels RA. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 875-880.
28. Lehnigk B, Rabe KF, Dent G, Herst RS, Carpentier PJ, Magnussen H. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced need bronchoconstriction and urinary LTE4 in asthmatic patients. Eur Respir J 1998; 11: 617-623.
29. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339: 147-152.
30. Ishii Y, Kitamura S. Hyperventilation stimulates the release of prostaglandin 12 and E2 from lung in humans. Prostaglandins 1990; 39: 685-691.
31. Hashimoto S, Matsumoto K, Yasuhiro G, Tomoko N, Ikuko T, Horie T. Hyperosmolarity-induced IL-8 expression in human bronchial epithelial cells through p38 mitogen-activated kinase. Am J Respir Crit Care Med 2000; 159: 634-640.
32. Lee TH, Nagakura T, Papageorgiou N, Cromwell O, Iikura Y, Kay AB. Mediators in exercise-induced asthma. J Allergy Clin Immunol 1984; 73: 634-639.
33. Banner AS, Green J, O'Connor M. Relation of respiratory water loss to coughing after exercise. N Engl J Med 1984; 311: 883-886.
34. Ichinose M, Miura M, Yamauchi H, et al. A neurokinin 1 - receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am J Respir Crit Care Med 1996; 153: 936-941.
35. Konig P, Hordvik NL, Kreutz C. The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise-induced asthma (EIA) in adults. J Allergy Clin Immunol 1987; 79: 64-68.
36. Bianco S, Vaghi A, Robuschi M, Pasargiklian M. Prevention of exercise-induced bronchoconstriction by inhaled fruse-mide. Lancet 1988; 2: 252-255.
37. Waalkens HJ, van Essen-Zandvliet EE, Gerritsen J, Duiverman EJ, Kerrebijn KF, Knol K. The effect of an inhaled corticosteroid (budesonide) on exercise-induced asthma in children. Dutch CNSLD Study Group. Eur Respir J 1993: 6: 652-656.
38. Phillips GD, Ng WH, Church MK, Holgate ST. The response of plasma histamine to bronchoprovocation with methacholine, adenosine 5′-monophosphate, and allergen in atopic nonasthmatic subjects. Am Rev Respir Dis 1990; 141: 9-13.
39. Polosa R, Phillips GD, Rajakulasingam K, Holgate ST. The effect of inhaled ipratropium bromide alone and in combination with oral terfenadine on bronchoconstriction provoked by adenosine 5′-monophosphate and histamine in asthma. J Allergy Clin Immunol 1991; 87: 939-947.
40. Rafferty P, Beasley R, Holgate ST. The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5′ monophosphate in atopic asthma. Am Rev Respir Dis 1987; 136: 369-373.
41. Crimi N, Palermo F, Polosa R, et al. Effect of indomethacin on adenosine-induced bronchoconstriction. J Allergy Clin Immunol 1989; 83: 921-925.
42. Phillips GD, Holgate ST. The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5′-monophosphate in nonatopic asthma. Am Rev Respir Dis 1989; 139: 463-469.
43. Hughes PJ, Holgate ST, Church MK. Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. Biochem Pharmacol 1984; 33: 3847-3852.
44. Polosa R, Ng WH, Crimi N, et al. Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit Care Med 1995; 151: 624-629.
45. Phillips GD, Rafferty P, Beasley R, Holgate ST. Effect of oral terfenadine on the bronchoconstrictor response to inhaled histamine and adenosine 5′-monophosphate in non-atopic asthma. Thorax 1987; 42: 939-945.
46. Crimi N, Polosa R, Magri S, et al. Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5′-monophosphate (AMP) in asthmatic subjects. Eur Respir J 1995; 8: 905-912.
47. Wang M, Wisniewski A, Pavord I, Knox A, Tattersfield A. Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5′-monophosphate challenge in asthma. Thorax 1996; 51: 799-804.
48. Crimi N, Palermo F, Oliveri R, Polosa R, Settinieri I, Mistretta A. Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine in asthma. Eur Respir J 1992; 5: 560-565.
49. Polosa R, Santonocito G, Magri S, et al. Neutral endopeptidase inhibition with inhaled phosphoramidon: no effect on bronchial responsiveness to adenosine 5′-monophosphate (AMP) in asthma. Eur Respir J 1997; 10: 2460-2464.
50. Naline E, Molimard M, Regoli D, Emonds-Alt X, Bellamy JF, Advenier C. Evidence for functional tachykinin NK1 receptors on human isolated small bronchi. Am J Physiol 1996; 271: L763-L767.
51. Ichinose M, Nakajima N, Takahashi T, Yamauchi H, Inoue H, Takishima T. Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet 1992; 340: 1248-1251.
52. Joos GF, Van Schoor J, Kips JC, Pauwels RA. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics. Am J Respir Crit Care Med 1996; 153: 1781-1784.
53. Heaney LG, Cross LJ, Stanford CF, Ennis M. Substance P induces histamine release from human pulmonary mast cells. Clin Exp Allergy 1995; 25: 179-186.
54. Joos G, Van De Velde V, Schelfhout V, Pauwels R. The leukotriene receptor antagonist zafirlukast inhibits neurokinin-A induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 2001; 163: A418.
55. Joos G, Pauwels R, Van Der Straeten M. The effect of oxitropium bromide on neurokinin A-induced bronchoconstriction in asthmatic subjects. Pulm Pharmacol 1988; 1: 41-45.
56. Crimi N, Palermo F, Oliveri R, et al. Influence of anti-histamine (astemizole) and anticholinergic drugs (ipratropium bromide) on bronchoconstriction induced by substance P. Ann Allergy 1990; 65: 115-120.
57. Molimard M, Martin CA, Naline E, Hirsch A, Advenier C. Contractile effects of bradykinin on the isolated human small bronchus. Am J Respir Crit Care Med 1994; 149: 123-127.
58. Hulsmann AR, Raatgeep HR, Saxena PR, Kerrebijn KF, de Jongste JC. Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin B-2 and thromboxane prostanoid receptors. Am J Respir Crit Care Med 1994; 150: 1012-1018.
59. Polosa R, Phillips GD, Lai CK, Holgate ST. Contribution of histamine and prostanoids to bronchoconstriction provoked by inhaled bradykinin in atopic asthma. Allergy 1990; 45: 174-182.
60. Fuller RW, Dixon CM, Cuss FM, Barnes PJ. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis 1987; 135: 176-180.
61. Schmidt D, Jorres RA, Rabe KF, Magnussen H. Reproducibility of airway response to inhaled bradykinin and effect of the neurokinin receptor antagonist FK-224 in asthmatic subjects. Eur J Clin Pharmacol 1996; 50: 269-273.
62. Polosa R, Milazzo VL, Magri S, et al. Activity of inhaled lysine acetylsalicylate (L-ASA) on bradykinin- induced bronchoconstriction in asthmatics: evidence of contribution of prostaglandins. Eur Respir J 1997; 10: 866-871.
63. del Bufalo C, Fasano L, Patalano F, Gunella G. Inhibition of fog-induced bronchoconstriction by nedocromil sodium and sodium cromoglycate in intrinsic asthma: a double-blind, placebo- controlled study. Respiralion 1989; 55: 181-185.
64. Ind PW, Barnes PJ, Durham SR, Kay AB. Propranolol-induced bronchoconstriction in asthma: beta-receptor blockade and mediator release. Am Rev Respir Dis 1984; 129: Suppl. A10.
65. Carpentiere G, Castello F, Marino S. Effect of oral terfenadine on the bronchoconstrictor response to inhaled propranolol and histamine in asthmatics. Curr Ther Res 1991; 49: 507-513.
66. Ind PW, Dixon CM, Fuller RW, Barnes PJ. Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis 1989; 139: 1390-1394.
67. Okayama M, Yafuso N, Nogami H, et al. A new method of inhalation challenge with propranolol: comparison with methacholine-induced bronchoconstriction and role of vagal nerve activity. J Allergy Clin Immunol 1987; 80: 291-299.
68. Koeter GH, Meurs H, Jonkman JH, et al. Protective effect of oral oxyphenonium bromide, terbutaline and theophylline against the bronchial obstructive effects of inhaled histamine, acetylcholine and propranolol. Eur J Clin Pharmacol 1984; 26: 435-441.
69. Pavord ID, Wisniewski A, Tattersfield AE. Refractoriness to inhaled sodium metabisulphite in subjects with mild asthma. Eur Respir J 1994; 7: 50-54.
70. Field PI, Simmul R, Bell SC, Allen DH, Berend N. Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction. Thorax 1996; 51: 159-163.
71. Lazarus SC, Wong HH, Watts MJ, Boushey HA, Lavins BJ, Minkwitz MC. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide- induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1997; 156: 1725-1730.
72. Nadel JA, Salem H, Tamplin B, Tokiwa Y. Mechanism of bronchoconstriction during inhalation of sulfur dioxide. J Appl Physiol 1965; 20: 164-167.
73. Sheppard D, Wong WS, Uehara CF, Nadel JA, Boushey HA. Lower threshold and greater bronchomotor responsiveness of asthmatic subjects to sulfur dioxide. Am Rev Respir Dis 1980; 122: 873-878.
74. Bellingan GJ, Dixon CM, Ind PW. Inhibition of inhaled metabisulphite-induced bronchoconstriction by inhaled frusemide and ipratropium bromide. Br J Clin Pharmacol 1992; 34: 71-74.
75. Bellofiore S, Caltagirone F, Pennisi A, Ciancio N, Mistretta A, Di Maria GU. Neutral endopeptidase inhibitor thiorphan increases airway narrowing to inhaled sodium metabisulfite in normal subjects. Am J Respir Crit Care Med 1994; 150: 853-856.
76. Boulet LP, Turcotte H, Tennina S. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the Prevention of bronchospasm induced by exercise and hyperosmolar challenges. J Allergy Clin Immunol 1989; 83: 882-887.
77. Anderson SD, Holzer K. Exercise-induced asthma: Is it the right diagnosis in elite athletes? J Allergy Clin Immunol 2000; 106: 419-428.
78. Shimizu T, Mochizuki H, Shigeta M, Morikawa A. Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma. Am J Respir Crit Care Med 1997; 155: 170-173.
79. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992; 145: 746-749.
80. Robuschi M, Riva E, Fuccella LM, et al. Prevention of excercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992; 145: 1285-1288.
81. Dorward AJ, Patel KR. A comparison of ketotifen with clemastine, ipratropium bromide and sodium cromoglycate in exercise-induced asthma. Clin Allergy 1982; 12: 355-361.
82. Tullett WM, Patel KR, Berkin KE, Kerr JW. Effect of lignocaine, sodium cromoglycate, and ipratropium bromide in exercise-induced asthma. Thorax 1982; 37: 737-740.
83. Jongejan RC, de Jongste JC, Raatgeep RC, Stijnen T, Bonta IL, Kerrebijn KF. Effects of hyperosmolarity on human isolated central airways. Br J Pharmacol 1991; 102: 931-937.
84. Gravelyn TR, Pan PM, Eschenbacher WL. Mediator release in an isolated airway segment in subjects with asthma. Am Rev Respir Dis 1988; 137: 641-646.
85. Finnerty JP, Wilmot C, Holgate ST. Inhibition of hypertonic saline-induced bronchoconstriction by terfenadine and flurbiprofen. Evidence for the predominant role of histamine. Am Rev Respir Dis 1989; 140: 593-597.
86. Brannan JD, Anderson SD, Gomes K, King GG, Chan H-K, Scale JP. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420-1425.
87. Makker HK, Holgate ST. The contribution of neurogenic reflexes to hypertonic saline-induced bronchoconstriction in asthma. J Allergy Clin Immunol 1993; 92: 82-88.
88. Altounyan REC, Lee TB, Rocchiccioli MS, Shaw CL. A comparison of the inhibitory effects of nedocromil sodium and sodium cromoglycate on adenosine monophosphate-induced bronchoconstriction in atopic subjects. Eur J Respir Dis 1986: 69: Suppl. 277-279.
89. Badier M, Beaumont D, Orehek J. Attenuation of hyperventilation-induced bronchospasm by terfenadine: a new antihistamine. J Allergy Clin Immunol 1988; 81: 437-440.
90. Finnerty JP, Harvey A, Holgate ST. The relative contributions of histamine and prostanoids to bronchoconstriction provoked by isocapnic hyperventilation in asthma. Eur Respir J 1992; 5: 323-330.
91. Fischer AR, McFadden CA, Frantz R, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995; 152: 1203-1207.
92. Sheppard D, Epstein J, Holtzman MJ, Nadel JA, Boushey HA. Dose-dependent inhibition of cold-air-induced bronchoconstriction by atropine. J Appl Physiol 1982; 53: 169-174.
93. Wilson N, Dixon C, Silverman M. Bronchial responsiveness to hyperventilation in children with asthma: inhibition with ipratropium bromide. Thorax 1984: 39: 588-593.
94. Myers JD, Bigby BG, Calvayrac P, Sheppard D, Boushey HA. Interaction of cromolyn and a muscarinic antagonist in inhibiting bronchial reactivity to sulfur dioxide and to eucapnic hyperpnea alone. Am Rev Respir Dis 1986; 133: 1154-1158.
95. Schellenberg RR. Airway responses to platelet-activating factor. Am Rev Respir Dis 1987; 136: S28-S32.
96. Dahlen B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6: 1018-1026.
97. Wood-Baker R, Finnerty JP, Holgate ST. Plasma and urinary histamine in allergen-induced early and late phase asthmatic responses. Eur Respir J 1993; 6: 1138-1144.
98. Twentyman OP, Ollier S, Holgate ST. The effect of H1-receptor blockade on the development of early- and late-phase bronchoconstriction and increased bronchial responsiveness in allergen-induced asthma. J Allergy Clin Immunol 1993; 91: 1169-1178.
99. Sladek K, Sheller JR, FitzGerald GA, Morrow JD, Roberts LJ. Formation of PGD2 after allergen inhalation in atopic asthmatics. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A: 433-436.
100. Macfarlane AJ, Dworski R, Sheller JR, Pavord ID, Kay AB, Barnes NC. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am J Respir Crit Care Med 2000: 161: 1553-1558.
101. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993; 147: 839-844.
102. Diamant Z, van der Veen H, Kuijpers EA, Bakker PF, Sterk PJ. The effect of inhaled thiorphan on allergen-induced airway responses in asthmatic subjects. Clin Exp Allergy 1996; 26: 525-532.
103. Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-1863.
104. Fredholm BB, Arslan G, Kull B, Kontny E, Svenningsson P. Adenosine (P1) receptor signalling. Drug Dev Res 1996; 39: 262-268.
105. Feoktistov I, Polosa R, Holgate ST, Biaggioni I. Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol Sci 1998; 19: 148-153.
106. Joos G, Pauwels RA. Adenosine receptors involved in the bronchoconstrictor effect of adenosine. Drug Dev Res 1996; 39: 330-332.
107. Maggi CA. Tachykinin receptors and airway pathophysiology. Eur Respir J 1993; 6: 735-742.
108. Naline E, Devillier P, Drapeau G, et al. Characterization of neurokinin effects and receptor selectivity in human isolated bronchi. Am Rev Respir Dis 1989; 140: 679-686.
109. Advenier C, Naline E, Toty I, et al. Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK2) receptors. Am Rev Respir Dis 1992; 146: 1177-1181.
110. Ellis JL, Undem BJ, Kays JS, Ghanekar SV, Barthlow HG, Buckner CK. Pharmacological examination of receptors mediating contractile responses to tachykinins in airways isolated from human, guinea pig and hamster. J Pharmacol Exp Ther 1993; 267: 95-101.
111. Amadesi S, Moreau J, Tognetto M, et al. NK1 receptor stimulation causes contraction and inositol phosphate increase in medium-size human isolated bronchi. Am J Respir Crit Care Med 2001; 163: 1206-1211.
112. Joos GF, Pauwels RA, Van der Straeten ME. The effect of nedocromil sodium on the bronchoconstrictor effect of neurokinin A in subjects with asthma. J Allergy Clin Immunol 1989; 83: 663-668.
113. Joos GF, Pauwels RA. Pro-inflammatory effects of substance P: new perspectives for the treatment of airway diseases? Trends Pharmacol Sci 2000; 21: 131-133.
114. Van Schoor J, Joos GF, Chasson BL, Brouard RJ, Pauwels RA. The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur Respir J 1998; 12: 17-23.
115. Di Maria GU, Bellofiore S, Geppetti P. Regulation of airway neurogenic inflammation by neutral endopeptidase. Eur Respir J 1998; 12: 1454-1462.
116. Cheung D, Timmers MC, Zwinderman AH, den Hartigh J, Dijkman JH, Sterk PJ. Neutral endopeptidase activity and airway hyperresponsiveness to neurokinin A in asthmatic subjects in vivo. Am Rev Respir Dis 1993: 148: 1467-1473.
117. Nadel JA. Peptidase modulation of neurogenic inflammation. In: Geppetti P, Holzer P, ed. Neurogenic inflammation. Boca Raton, CRC Press, 1996; 115-127.
118. Polosa R, Holgate ST. Comparative airway response to inhaled bradykinin, kallidin, and [des- Arg9] bradykinin in normal and asthmatic subjects. Am Rev Respir Dis 1990; 142: 1367-1371.
119. Proud D. Kinins as mediators of lung disease. In: Crystal RG, West JB, Barnes PJ, Weibel ER, eds. The Lung. Philadelphia, Lippincott Raven, 1997; 89-101.
120. Ricciardolo FL, Geppetti P, Mistretta A, et al. Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma. Lancet 1996; 348: 374-377.
121. Geppetti P. Sensory neuropeptide release by bradykinin: mechanisms and pathophysiological implications. Regul Pept 1993; 47: 1-23.
122. Ichinose M, Belvisi MG, Barnes PJ. Bradykinin-induced bronchoconstriction in guinea pig in vivo: role of neural mechanisms. J Pharmacol Exp Ther 1990; 253: 594-599.
123. Saria A, Martling CR, Yan Z, Theodorsson-Norheim E, Gamse R, Lundberg JM. Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation. Am Rev Respir Dis 1988; 137: 1330-1335.
124. Adelroth E, Hargreave FE, Ramsdale EH. Do physicians need objective measurements to diagnose asthma? Am Rev Respir Dis 1986; 134: 704-707.
125. Woolcock AJ, Anderson SD, Peat JK, et al. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis 1991; 143: 1438-1443.
126. Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7: 235-243.
127. Juniper EF, Cockcroft DW, Hargreave FE. Histamine and methacholine inhalatation tests: tidal breathing method - laboratory procedure and standardisation. Lund, Sweden, AB Draco, 1994.
128. Chai H, Farr RS, Froehlich LA, et al. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975; 56: 323-327.
129. Ryan G, Dolovich MB, Obminski G, et al. Standardization of inhalation provocation tests: influence of nebuliser output, particle size, and method of inhalation. J Allergy Clin Immunol 1981; 67: 156-161.
130. Yan K, Salome C, Woolcock AJ. Rapid method for measurement of bronchial responsiveness. Thorax 1983; 38: 760-765.
131. Juniper EF, Frith PA, Dunnett C, Cockcroft DW, Hargreave FE. Reproducibility and comparison of responses to inhaled histamine and methacholine. Thorax 1978; 33: 705-710.
132. Woolcock AJ. Expression of results of airway hyperresponsiveness. In: Hargreave FE, Woolcock AJ, eds. Airway Hyperresponsiveness Measurement and Interpretation. Canada, Astra Pharmaceuticals Canada Ltd, 1985; pp. 80-90.
133. Dehaut P, Rachiele A, Martin RR, Malo JL. Histamine dose-response curves in asthma: reproducibility and sensitivity of different indices to assess response. Thorax 1983; 38: 516-522.
134. Townley RG, Bewtra AK, Nair NM, Brodkey FD, Watt GD, Burke KM. Methacholine inhalation challenge studies. J Allery Clin Immunol 1979; 64: 569-574.
135. Hopp RJ, Bewtra AK, Nair NM, Townley RG. Specificity and sensitivity of methacholine inhalation challenge in normal and asthmatic children. J Allergy Clin Immunol 1984; 74: 154-158.
136. Backer V, Groth S, Dirksen A, et al. Sensitivity and specificity of the histamine challenge test for the diagnosis of asthma in an unselected sample of children and adolescents. Eur Respir J 1991; 4: 1093-1100.
137. Cockcroft DW, Murdock KY, Berscheid BA, Gore BP. Sensitivity and specificity of histamine PC20 determination in a random selection of young college students. J Allergy Clin Immunol 1992; 89: 23-30.
138. Ramsdell JW, Nachtwey FJ, Moser KM. Bronchial hyperreactivity in chronic obstructive bronchitis. Am Rev Respir Dis 1982; 126: 829-832.
139. Ramsdale EH, Morris MM, Roberts RS, Hargreave FE. Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness. Thorax 1984; 39: 912-918.
140. Ramsdale EH, Roberts RS, Morris MM, Hargreave FE. Differences in responsiveness to hyperventilation and methacholine in asthma and chronic bronchitis. Thorax 1985; 40: 422-426.
141. Verma VK, Cockcroft DW, Dosman JA. Airway responsiveness to inhaled histamine in chronic obstructive airways disease. Chronic bronchitis vs emphysema. Chest 1988; 94: 457-461.
142. Anderton RC, Cuff MT, Frith PA, Cockcroft DW, Morse JL, Jones NL, et al. Bronchial responsiveness to inhaled histamine and exercise. J Allergy Clin Immunol 1979; 63: 315-320.
143. Eggleston PA. A comparison of the asthmatic response to methacholine and exercise. J Allergy Clin Immunol 1979; 63: 104-110.
144. Shapiro GG. Methacholine challenge - relevance for the allergic athlete. J Allergy Clin Immunol 1984; 73: 670-675.
145. Fourie PR, Joubert JR. Determination of airway hyperreactivity in asthmatic children: a comparison among exercise, nebulized water, and histamine challenge. Pediatr Pulmonol 1988; 4: 2-7.
146. Lin CC, Wu JL, Huang WC, Lin CY. A bronchial response comparison of exercise and methacholine in asthmatic subjects. J Asthma 1991; 28: 31-40.
147. Eliasson AH, Phillips YY, Rajagopal KR, Howard RS. Sensitivity and specificity of bronchial provocation testing. An evaluation of four techniques in exercise-induced bronchospasm. Chest 1992; 102: 347-355.
148. Vasar M, Braback L, Julge K, Knutsson A, Riikjarv MA, Bjorksten B. Prevalence of bronchial hyperreactivity as determined by several methods among Estonian school-children. Pediatr Allergy Immunol 1996; 7: 141-146.
149. Godfrey S, Springer C, Bar-Yishay E, Avital A. Cut-off points defining normal and asthmatic bronchial reactivity to exercise and inhalation challenges in children and young adults. Eur Respir J 1999; 14: 659-668.
150. Holzer K, Anderson SD, Douglass J. Exercise in elite summer athletes: Challenges for diagnosis. J Allergy Clin Immunol 2002; 110: 374-380.
151. Godfrey S, Springer C, Noviski N, Maayan C, Avital A. Exercise but not methacholine differentiates asthma from chronic lung disease in children. Thorax 1991; 46: 488-492.
152. Avital A, Springer C, Bar-Yishay E, Godfrey S. Adenosine, methacholine, and exercise challenges in children with asthma or paediatric chronic obstructive pulmonary disease. Thorax 1995; 50: 511-516.
153. Benckhuijsen J, van den Bos JW, van Velzen E, de Bruijn R, Aalbers R. Differences in the effect of allergen avoidance on bronchial hyperresponsiveness as measured by methacholine, adenosine 5′-monophosphate, and exercise in asthmatic children. Pediatr Pulmonol 1996; 22: 147-153.
154. Yoshikawa T, Shoji S, Fujii T, et al. Severity of exercise-induced bronchoconstriction is related to airway eosinophilic inflammation in patients with asthma. Eur Respir J 1998; 12: 879-884.
155. Guidelines for Methacholine and Exercise Challenge Testing-1999. Am J Respir Crit Care Med 2000; 161: 309-329.
156. Anderson SD, Argyros GJ, Magnussen H, Holzer K. Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction. Br J Sports Med 2001; 35: 344-347.
157. Steinbrugger B, Eber E, Modl M, Weinhandl E, Zach MS. A comparison of a single-step cold-dry air challenge and a routine histamine provocation for the assessment of bronchial responsiveness in children and adolescents. Chest 1995; 108: 741-745.
158. Nielsen KG, Bisgaard H. Lung Function Response to Cold Air Challenge in Asthmatic and Healthy Children of 2-5 Years of Age. Am J Respir Crit Care Med 2000; 161: 1805-1809.
159. Sont JK, Booms P, Bel EH, Vandenbroucke JP, Sterk PJ. The determinants of airway hyperresponsiveness to hypertonic saline in atopic asthma in vivo. Relationship with sub-populations of peripheral blood leucocytes. Clin Exp Allergy 1993; 23: 678-688.
160. Anderson SD, Gibson P. The use of aerosols of hypertonic saline and distilled water (fog) for the patient with asthma. In: Barnes PJ, Grunstein MM, Leff A, Woolcock AJ, ed. Asthma. New York, Raven Press, 1997; pp. 1135-1150.
161. Anderson SD, Brannan J, Spring J, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997; 156: 758-765.
162. Brannan JD, Koskela H, Anderson SD, Chew N. Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma. Am J Respir Crit Care Med 1998; 158: 1120-1126.
163. Riedler J, Reade T, Dalton M, Holst D, Robertson C. Hypertonic saline challenge in an epidemiologic survey of asthma in children. Am J Respir Crit Care Med 1994; 150: 1632-1639.
164. Rabone SJ, Phoon WO, Anderson SD, et al. Hypertonic saline challenge in an adult epidemiological survey. Occup Med (Lond) 1996; 46: 177-185.
165. Smith CM, Anderson SD. Inhalational challenge using hypertonic saline in asthmatic subjects: a comparison with responses to hyperpnoea, methacholine and water. Eur Respir J 1990; 3: 144-151.
166. Belcher NG, Lee TH, Rees PJ. Airway responses to hypertonic
167. Anderson SD, Brannan J, Trevillion L, Young I. Lung function and bronchial provocation tests for intending divers with a history of asthma. SPUMS Journal 1995; 25: 233-248.
168. Chua HL, Collis GG, Le Souef PN. Bronchial response to nebulized antibiotics in children with cystic fibrosis. Eur Respir J 1990; 3: 1114-1116.
169. Daviskas E, Anderson SD, Gonda I, et al. Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. Eur Respir J 1996; 9: 725-732.
170. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999; 159: 1843-1848.
171. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14: 678-685.
172. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996; 21: 77-83.
173. Rodwell LT, Anderson SD. Airway responsiveness to hyperosmolar saline challenge in cystic fibrosis: a pilot study. Pediatr Pulmonol 1996; 21: 282-289.
174. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 1984; 129: 211-215.
175. Sheppard D, Rizk NW, Boushey HA, Bethel RA. Mechanism of cough and bronchoconstriction induced by distilled water aerosol. Am Rev Respir Dis 1983; 127: 691-694.
176. Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25-29.
177. Fahy JV, Wong H, Liu J, Boushey HA. Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects. Am J Respir Crit Care Med 1995; 152: 53-58.
178. Gibson PG, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. J Allergy Clin Immunol 2000; 105: 752-759.
179. In't Veen JC, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ, Bel EH. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med 1999; 160: 93-99.
180. Iredale MJ, Wanklyn SA, Phillips IP, Krausz T, Ind PW. Non-invasive assessment of bronchial inflammation in asthma: no correlation between eosinophilia of induced sputum and bronchial responsiveness to inhaled hypertonic saline. Clin Exp Allergy 1994; 24: 940-945.
181. Allegra L, Bianco S. Non-specific broncho-reactivity obtained with an ultrasonic aerosol of distilled water. Eur J Respir Dis. 1980; 61: Suppl. 106, 41-49.
182. Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. Br Med J 1981; 283: 1285-1287.
183. Sheppard D, Rizk NW, Boushey HA, Bethel RA. Mechanism of cough and bronchoconstriction induced by distilled water aerosol. Am Rev Respir Dis 1983; 127: 691-694.
184. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 1984; 129: 211-215.
185. Anderson SD. Bronchial challenge by ultrasonically nebulized aerosols. Clin Rev Allergy 1985; 3: 427-439.
186. Anderson SD. Non-isotonic aerosol challenge in the evaluation of bronchial hyperresponsiveness. Allergy Proc 1991; 12: 143-149.
187. Foresi A, Mattoli S, Corbo GM, Polidori G, Ciappi G. Comparison of bronchial responses to ultrasonically nebulized distilled water, exercise, and methacholine in asthma. Chest 1986; 90: 822-826.
188. Mattoli S, Foresi A, Corbo GM, et al. Refractory period to ultrasonic mist of distilled water: relationship to methacholine responsiveness, atopic status, and clinical characteristics. Ann Allergy 1987; 58: 134-140.
189. Groot C, Lammers JW, Festen J, van Herwaarden C. Refractoriness for ultrasonically nebulized distilled water and histamine after histamine challenge. J Appl Physiol 1991: 70: 1011-1015.
190. Kivity S, Shalit Y, Greif J, Topilsky M. Comparison between refractoriness after distilled water-induced asthma and exercise-induced asthma. Ann Allergy 1989: 62: 180-183.
191. Cushley MJ, Tattersfield AE, Holgate ST. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 1983; 15: 161-165.
192. Polosa R, Pagano C, Prosperini G, et al. Histamine release upon adenosine 5′-monophosphate (AMP) nasal provocation in allergic subjects. Thorax 1999; 54: 230-233.
193. Oosterhoff Y, de Jong JW, Jansen MA, Koeter GH, Postma DS. Airway responsiveness to adenosine 5′-monophosphate in chronic obstructive pulmonary disease is determined by smoking. Am Rev Respir Dis 1993; 147: 553-558.
194. Chetta A, Foresi A, Garavaldi G, Corbo GM, Cuomo A, Olivieri D. Evaluation of bronchial responsiveness by pharmacological challenges in asthma. Inhaled propranolol in comparison with histamine and methacholine. Respiration 1988; 54: Suppl. 1, 84-89.
195. Woolcock AJ, Cheung W, Salome C. Relationship between bronchial responsiveness to propranolol and histamine. Am J Respir Crit Care Med 1986; 133: A177.
196. Nowak D, Jorres R, Berger J, Claussen M, Magnussen H. Airway responsiveness to sulfur dioxide in an adult population sample. Am J Respir Crit Care Med 1997; 156: 1151-1156.
197. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104: 5-13.
198. Bianco S, Robuschi M, Petrini G. Aspirin-induced tolerance in aspirin-asthma detected by a new challenge test. IRCS J Med Sci 1997; 5: 129.
199. Phillips GD, Foord R, Holgate ST. Inhaled lysine-aspirin as a bronchoprovocation procedure in aspirin-sensitive asthma: its repeatability, absence of a late-phase reaction, and the role of histamine. J Allergy Clin Immunol 1989; 84: 232-241.
200. Dahlen B, Zetterström O. Comparison of bronchial and per oral provocation with aspirin in aspirin-sensitive asthmatics. Eur Respir J 1990; 3: 527-534.
201. Melillo G, Padovano A, Cocco G, Masi C. Dosimeter inhalation test with lysine acetylsalicylate for the detection of aspirin-induced asthma. Ann Allergy 1993; 71: 61-65.
202. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982; 69: 11-19.
203. Nizankowska E, Szczeklik A. Glucocorticosteroids attenuate aspirin-precipitated adverse reactions in aspirin-intolerant patients with asthma. Ann Allergy 1989; 63: 159-162.
204. Szczeklik A, Dworski R, Mastalerz L, et al. Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. Am J Respir Crit Care Med 1998; 158: 1168-1172.
205. Gibson PG. Monitoring the patient with asthma: an evidence-based approach. J Allergy Clin Immunol 2000; 106: 17-26
206. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142: 832-836.
207. Kerrebijn KF, van Essen-Zandvliet FE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653-659.
208. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159: 1043-1051.
209. Polosa R, Ciamarra I, Mangano G, et al. Bronchial hyperresponsiveness and airway inflammation markers in nonasthmatics with allergic rhinitis. Eur Respir J 2000; 15: 30-35.
210. O'Connor BJ, Ridge SM, Barnes PJ, Fuller RW. Greater effect of inhaled budesonide on adenosine 5′-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma. Am Rev Respir Dis 1992; 146: 560-564.
211. Doull l, Sandall D, Smith S, Schreiber J, Freezer NJ, Holgate ST. Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 5′ monophosphate, methacholine, and bradykinin in symptomatic children with recurrent wheeze. Pediatr Pulmonol 1997; 23: 404-411.
212. O'Connor BJ, Fuller RW, Barnes PJ. Nonbronchodilator effects of inhaled beta 2 agonists. Greater protection against adenosine monophosphate- than methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1994; 150: 381-387.
213. O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med 1992; 327: 1204-1208.
214. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163: 406-412.
215. Rodwell LT, Anderson SD, Seale JP. Inhaled steroids modify bronchial responses to hyperosmolar saline. Eur Respir J 1992; 5: 953-962.
216. Brannan JD, Anderson SD, Freed R, Leuppi JD, Koskela H, Chan HK. Nedocromil sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects. Am J Respir Crit Care Med 2000; 161: 2096-2099.
217. Anderson SD, Du Toit JI, Rodwell LT, Jenkins CR. Acute effect of sodium cromoglycate on airway narrowing induced by 4.5 percent saline aerosol. Outcome before and during treatment with aerosol corticosteroids in patients with asthma. Chest 1994; 105: 673-680.
218. Brannan J, Koskela H, Anderson SD, Chan HK, Kim H. Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects. Respirology 2002; 7: 37-44.
219. de Vries K, Booij-Noord H, Van der Lende R, Van Lookeren Campagne JG, Orie NGM. Reactivity of the bronchial tree to different stimuli. Les Bronches 1968; 18: 439-542.
220. Jayaram L, Parameswaran K, Sears MR, Hargreave FE. Induced sputum cell counts: their usefulness in clinical practice. Eur Respir J 2000; 16: 150-158.
221. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995; 95: 29-33.
222. Wiebicke W, Jorres R, Magnussen H. Comparison of the effects of inhaled corticosteroids on the airway response to histamine, methacholine, hyperventilation, and sulfur dioxide in subjects with asthma. J Allergy Clin Immunol 1990; 86: 915-923.
223. Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air hyperventilation in patients with asthma. Thorax 1991; 46: 811-816.
224. Fuller RW, Choudry NB, Eriksson G. Action of budesonide on asthmatic bronchial hyperresponsiveness. Effects on directly and indirectly acting bronchoconstrictors. Chest 1991; 100: 670-674.
225. Groot CAR, Lammers JWJ, Molema J, Festen J, van Herwaarden CLA. Effect of inhaled beclomethasone and nedocromil sodium on bronchial hyperresponsiveness to histamine and distilled water. Eur Respir J 1992; 5: 1075-1082.
226. Bootsma GP, Dekhuijzen PN, Festen J, Mulder PG, van Herwaarden CL. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax 1995; 50: 1044-1050.
227. Weersink EJ, Douma RR, Postma DS, Koeter GH. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am J Respir Crit Care Med 1997; 155: 1241-1246.
228. van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC(20) of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC(20) of methacholine. Am J Respir Crit Care Med 2001; 164: 1127-1132.
229. Haby MM, Peat JK, Mellis CM, Anderson SD, Woolcock AJ. An exercise challenge for epidermiological studies of childhood asthma: validity and repeatability. Eur Respir J 1995; 8: 729-736.
230. Salome CM, Peat JK, Britton WJ, Woolcock AJ. Bronchial hyperresponsiveness in two populations of Australian schoolchildren. 1. Relation to respiratory symptoms and diagnosed asthma. Clin Allergy 1987; 17: 271-281.
231. Saetta M, Di Stefano A, Turato G, et al. Fatal asthma attack during an inhalation challenge with ultrasonically nebulized distilled water. J Allergy Clin Immunol 1995; 95: 1285-1287.
232. Wong HG, Fahy JV. Safety of one method of sputum induction in asthmatic subjects. Am J Respir Crit Care Med 1997; 156: 299-303.
233. Jones PD, Hankin R, Simpson J, Gibson PG, Henry RL. The tolerability, safety, and success of sputum induction and combined hypertonic saline challenge in children. Am J Respir Crit Care Med 2001; 164: 1146-1149.
234. Mann JS, Holgate ST. Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline. Br J Clin Pharmacol 1985; 19: 685-692.
235. Crimi N, Palermo F, Oliveri R, et al. Comparative study of the effects of nedocromil sodium (4 mg) and sodium cromoglycate (10 mg) on adenosine-induced bronchoconstriction in asthmatic subjects. Clin Allergy 1988; 18: 367-374.
236. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996; 153: 931-935.
237. Dahlen B. Leukotrienes as mediators of asthma induced by aspirin and allergen. Karolinska Instituet, Stockholm, Sweden (PhD). 1993.